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Abstract
Background: Non-adherence to anti-psychotics is common, expensive and affects recovery. We therefore examine
the cost-effectiveness of adherence therapy for people with schizophrenia by multi-centre randomised trial in
Amsterdam, London, Leipzig and Verona.
Methods: Participants received 8 sessions of adherence therapy or health education. We measured lost productivity
and use of health/social care, criminal justice system and informal care at baseline and one year to estimate and
compare mean total costs from health/social care and societal perspectives. Outcomes were the Short Form
36 (SF-36) mental component score (MCS) and quality-adjusted life years (QALYs) gained (SF-36 and EuroQoL 5
dimension (EQ5D)). Cost-effectiveness was examined for all cost and outcome combinations using cost-effectiveness
acceptability curves (CEACs).
Results: 409 participants were recruited. There were no cost or outcome differences between adherence therapy
and health education. The probability of adherence therapy being cost-effective compared to health education was
between 0.3 and 0.6 for the six cost-outcome combinations at the willingness to pay thresholds we examined.
Conclusions: Adherence therapy appears equivalent to health education. It is unclear whether it would have
performed differently against a treatment as usual control, whether such an intervention can impact on quality of life
in the short-term, or whether it is likely to be cost-effective in some sites but not others.
Trial registration: Current Controlled Trials ISRCTN: ISRCTN01816159.
Keywords: Cost effectiveness, Quality-adjusted life year, Antipsychotic, Adherence, Schizophrenia, Psychological
therapy
Background
Schizophrenia has notable impacts upon patients, their
families, services and the wider economy [1]. Due to its
chronic nature, the main aim of health and social care
interventions is to improve symptoms, long-term health
and quality of life. Treatments and services come at a
considerable cost and although it is entirely appropriate
to invest resources in helping those affected to manage
their illness, there are inevitable pressures to contain
costs and use budgets as effectively as possible. Non-
adherence (or non-compliance) with anti-psychotic
medication is common, due to the severe side-effects
that are associated with many of them, and is associated
with higher inpatient and total treatment costs [2]. Im-
proving medication adherence is therefore a potential
avenue for achieving savings in health care expenditure.
One potential approach is adherence therapy. It mainly
uses educational, cognitive-behavioural or motivational
techniques to encourage people with schizophrenia to
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adhere to their prescribed medication regime. There is
clearly a need for further discussion and research about
the effectiveness, let alone cost-effectiveness, of such
treatments as indicated by a recent questioning of the is-
suing and interpretation of National Institute for Health
and Care Excellence (NICE) guidance in England on this
matter [3]. In addition to general budget constraints,
there can also be resource constraints such as the rela-
tive lack of professionals trained in delivering such ther-
apies. Therefore, as well as exploring whether such
therapies can avoid unnecessary health care and other
costs, there is the additional economic dimension of ex-
ploring how these scarce psychological treatments
should be allocated.
We examined an adherence therapy as part of a large
multi-centre randomised controlled trial (Quality of Life
following Adherence Therapy for People Disabled by
Schizophrenia and their Carers; QUATRO). Effectiveness
evidence from that trial suggested that adherence ther-
apy was equivalent to health education in improving
quality of life [4]. It is now widely recognised that health
care decision-making should move away from inference
based on statistical significance [5] to avoid what
Claxton et al. [6] describe as the perverse (and costly)
situation of selecting a technology with the lowest
chance of being cost-effective. We therefore examined
the cost-effectiveness of adherence therapy using a
decision-making framework which incorporates any un-
certainty surrounding cost and outcomes data.
Methods
Full details of the trial have been described by Gray et al.
[4] To summarise, 409 participants with (a) a clinical
and research diagnosis of schizophrenia, (b) a need for
continuing anti-psychotic medication for at least a year
following baseline and (c) evidence of clinical instability
in the year before baseline were recruited between June
2002 and October 2003 from a range of general adult
psychiatric inpatient and community services at 4 cen-
tres: Amsterdam in the Netherlands; Croydon (hereafter
referred to as London) in England; Leipzig in Germany;
and Verona in Italy. Ethical approval was obtained by all
relevant local research ethics committees and participants
gave written informed consent: Institute of Psychiatry
Research Ethics Committee.
Interventions
Participants were randomised to receive either adherence
therapy or a health education package. Adherence therapy
was a pragmatic intervention based on motivational
interviewing and cognitive behavioural techniques, and
aimed to achieve concordance about medication between
the participant and therapist. It consisted of five key in-
terventions: medication problem solving; a medication
timeline; exploring ambivalence about medication;
discussing beliefs and concerns about medication; and
using medication in the future. The control interven-
tion, a health education package, aimed to control for
the time and non-specific effects of a therapeutic rela-
tionship. It provided information on a range of health
education topics (e.g. physical health, diet and health
and safety in the home), presented in a didactic way
without any adherence therapy techniques to clearly
differentiate it from the adherence therapy. Both inter-
ventions were delivered in routine clinical settings to
maximise generalisability. Treatment completion was
defined as attendance of at least 5 out of 8 sessions
(each lasting 30–50 minutes) over a maximum five-
month period.
Data collection
Comprehensive data were collected on all health, social
care and other relevant services used by individual study
members using a tailored version of the Client Socio-
demographic & Service Receipt Inventory (CSSRI-EU).
This was adapted from a version specifically developed
(with local language equivalents) for another European
study [7] and covered: socio-demographics; living situ-
ation/accommodation; education, employment and in-
come; time off work; use of health, social care and
criminal justice system resources; and informal care. It
was administered by face-to-face interview with partici-
pants (supplemented with information from key workers
and service providers where necessary) at baseline and at
one year follow-up, each time covering resource use for
the previous 3 months, except in the case of inpatient
stays, which were measured for the previous 12 months.
Resources related to the interventions were measured
in terms of the number of sessions attended by each
participant, the duration of each session and the non-
contact time spent by the therapist to prepare or follow-
up a session. Therapists extracted these data from their
patient case notes onto a study proforma.
Costs
Individual-level costs were calculated by multiplying
resource use quantities with country-specific unit costs
(Table 1). These were best available estimates from local
or national data for each country, based on guidelines
tested previously [8]. Alternative approaches were taken
for some resource costs. Firstly, some specialised accom-
modation unit costs were obtained directly from accom-
modation providers. Secondly, as it was infeasible to
collate country-specific unit costs for each of the huge
range of medications that patients were likely to report,
British medication unit costs were applied to all data
using gross domestic product purchasing power parities
(GDP PPPs) [9] to adjust for price levels in each country.
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Table 1 Unit costs in PPP-adjusted Euros (full details of sources and assumptions are available upon request from the
corresponding author)
Item Unit Amsterdam Leipzig London Verona
Interventions
Adherence therapy & health education Therapist hour 43.16 22.36 31.62 20.82
Earnings
National average wage Day 115.85 136.23 114.71 129.46
Accommodation
Overnight facility, 24 hours staffed Day 156.07 58.21 80.07 109.77
Overnight facility, staffed (not 24 hours) Day 70.94 58.21 15.20 17.66
Overnight facility, unstaffed Day 28.38 10.68 15.20 NA
Hospital inpatient services
Acute psychiatric ward Inpatient day 472.95 178.51 262.52 312.59
Psychiatric rehabilitation ward Inpatient day 197.06 178.51 262.52 253.20
Long-stay ward Inpatient day 75.22 178.51 200.08 168.80
Emergency/crisis centre Inpatient day 718.88 178.51 536.38 475.14
General medical ward Inpatient day 273.75 253.64 397.79 288.91
Hospital outpatient services
Psychiatric outpatients Attendance 49.14 46.41 137.64 56.28
Non-psychiatric outpatients Attendance 49.68 39.27 133.39 13.71
Day hospital Attendance 137.90 42.46 106.37 96.90
Community-based services
Community mental health centre Minute 0.29 0.43 1.39 0.10
Day care centre Minute 0.29 0.19 0.20 0.27
Group therapy Minute 0.33 0.50 0.23 0.23
Sheltered workshop Minute 2.31 3.45 0.17 1.68
Specialist education Minute 0.05 0.07 0.24 0.02
Community-based professionals
Psychiatrist Minute 1.10 1.22 4.97 0.98
Psychologist Minute 0.71 0.53 1.56 0.66
Primary care physician Minute 0.90 2.55 2.55 2.22
District nurse Minute 0.43 0.49 1.09 0.50
Community psychiatric nurse/case manager Minute 0.53 0.48 1.46 0.50
Social worker Minute 0.53 0.47 2.20 0.37
Occupational therapist Minute 0.53 0.47 0.88 0.34
Home help/care worker Minute 0.32 0.54 0.24 0.30
Criminal justice services*
Police Contact 119.08 119.04 83.93 119.17
Police cell or prison Night 28.97 28.96 20.42 28.99
Psychiatric assessment in custody Assessment 422.78 422.65 297.99 423.10
Criminal court Proceeding 1999.05 1998.46 1409.01 2000.57
Civil court Proceeding 1286.61 1286.22 906.85 1287.58
Medications*
Range for all used 100 milligrams 0.01 to 726.73 0.01 to 726.52 0.01 to 512.23 0.01 to 727.28
Shaded areas represent imputed unit costs.
*UK unit costs converted into PPP-adjusted Euros.
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Finally, the same approach was taken for criminal justice
system services given that relatively few people were
expected to use these services, such the costs were
expected to contribute little to total costs and relevant
cost data were not readily available. Inevitably we could
not locate/calculate some unit costs within the available
time and resources and we imputed these by calculating
ratios of one unit cost against another within each site
to account for differences in relative prices and then ap-
plying the average ratio across sites for the relevant ser-
vice. Reference services against which other services
were compared was selected on the basis of being in the
same service sector and all sites having a unit cost esti-
mate for it. Thus, all accommodation and hospital unit
costs were compared against the unit cost for an acute
psychiatric ward inpatient day, unit costs for community-
based services were compared against the unit cost for a
community mental health centre and unit costs for all
community-based professionals were compared against
the unit cost of a psychiatrist. Further details of unit cost
sources and assumptions are available in Patel [10] or
from the corresponding author.
Costs of adherence therapy and health education were
estimated by first calculating a cost per therapist hour
for each site; this was identical for both interventions be-
cause they were delivered by the same staff, but variable
between sites due to differing staff mixes (nurses versus
psychologists) and grades to deliver the interventions.
Individual-level intervention costs were then computed
by multiplying this with contact and non-contact time.
All costs were originally estimated at 2003 price levels
(the most recent study year for which financial informa-
tion was expected to be available at the time of unit cost
data collection). Where necessary, information from the
next most recent financial year was adjusted using
country-specific GDP inflation rates [11]. Discounting
was unnecessary as costs were only assessed for one
year.
Once costs for all resource items were estimated for
each participant, local cost values were converted into a
common currency, Euros, for the purpose of pooled ana-
lyses, using the following GDP PPP [9] conversion rates:
▪ 1 Dutch Euro = 0.952 PPP-adjusted Euros
▪ 1 German Euro = 0.924 PPP-adjusted Euros
▪ 1 UK pound sterling = 1.419 PPP-adjusted Euros
▪ 1 Italian Euro = 1.044 PPP-adjusted Euros
All costs reported here were subsequently inflated
to 2011 prices using country-specific GDP inflation
rates [12].
As inpatient data were reported for a one-year period
while other resource use data were reported for a 3-
month period (to improve accuracy), costs for the latter
were extrapolated (multiplied by 4) to also represent a
one-year period.
Outcomes
We focused on two outcomes for the economic evalu-
ation. Firstly, the trial’s primary outcome measure, the
mental component summary score (MCS) of the Medical
Outcome Study 36 Item Short Form Health Survey
(SF-36) [13] at one year. Secondly, quality-adjusted life
year (QALY) gains over one year. We have previously
reported that for this patient group, QALYs generated
from the SF-36 have better distributional properties
than those generated from the EuroQol 5-dimensional
health state measure (EQ-5D) [14,15] so we focused on
SF-36 derived QALYs and used the EQ-5D in sensitive
analyses. Utility weights for each measure [16,17] were
attached to health states at baseline and one year to
calculate QALYs using the total area under the curve
approach with linear interpolation between assessment
points (and baseline adjustment for comparisons) [18]. All
participant-reported outcome assessments were under-
taken face-to-face at baseline (prior to randomisation) and
at one year follow-up by assessors blinded to participants’
group allocation.
Cost-effectiveness and cost-utility analyses
We took two cost perspectives: (1) health and social care
and (2) societal. With two outcomes, plus an additional
sensitivity analysis using the EQ5D, there were six cost-
outcome combinations to link and examine.
First, we planned to calculate incremental cost-
effectiveness ratios (ICERs; mean cost difference divided
by mean outcome difference) for any combination showing
adherence therapy group to have both higher costs and
better outcomes.
Second, given difficulties around estimating confidence
intervals for ICERs and the potential for error in decision-
making based on statistical significance, we explored uncer-
tainty using a cost-effectiveness plane and cost-effectiveness
acceptability curves (CEACs) based on the net-benefit
approach [19].
A cost-effectiveness plane represents the additional
costs and additional outcomes of one intervention
against another. The location of a coordinate represents
which of four possible cost-effectiveness scenarios the
results fall into. We constructed a plane using boot-
strapped regressions (1000 replications) of study group
upon total health and social care costs and SF-36-based
QALYs, with covariates for baseline costs and utility re-
spectively. The resulting coefficients of group differences
were saved and plotted using a scatter graph.
CEACs represent the probability that one intervention
is cost-effective compared to another, accounting for
hypothetical monetary values that decision-makers may
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place on point improvements in each outcome. CEACs
were constructed by first calculating a series of net bene-
fits for each individual, using the following formula,
where λ represents how much value a decision-maker
may place on one additional unit of outcome:
Net benefit ¼ λ  outcomeð Þ  cost
We did this for λ values ranging between 0 to 50,000
Euros (in 10,000 Euro increments). Then, for each λ
value, we calculated differences in mean net benefits
between the two groups using non-parametric bootstrap
linear regressions (1000 repetitions) which included co-
variates for the baseline values of the same cost category
and outcome. Finally (again for each λ value), we counted
the proportion of times the adherence therapy group had
a greater net benefit than the health education group and
plotted these proportions as a CEAC for each cost-
outcome combination.
Analyses
Analyses were done in SPSS Version 12.0.1 [20] or Stata
Version 8.2 [21]. Costs and outcomes are presented as
mean values with standard deviations. Mean differences
and 95% confidence intervals (CIs) were obtained by
non-parametric bootstrap regressions (1000 repetitions) to
account for the non-normal distribution commonly found
in economic data. Although this was a randomised con-
trolled trial and participants in both groups were expected
to be balanced at baseline, baseline costs and outcomes
could be predictors of follow-up values. To provide more
relevant treatment-effect estimates [22], baseline costs and
outcomes were added as covariates for the calculation of
mean differences in costs and outcomes respectively (for
the ICERs) and mean differences in net benefits (for the
CEACs).
All participants were analysed according to the group
to which they were randomised. Those lost to follow-up
at 12 months were excluded from all analyses; at base-
line, these did not differ on the three outcome measures
but they had higher health and social care costs (mean
difference 18,152 Euros; 95% confidence interval: 1,669
to 39,646 Euros).
Missing items for the SF-36 MCS were dealt with as
per the instrument’s instructions. We excluded cases
with missing items on the SF-36 and EQ5D for the pur-
pose of utility calculations. There was relatively little
item non-response on the CSSRI-EU. Where this did
occur, missing values were imputed to enable calculation
of total costs for as many participants as possible. A value
of zero was assumed where there was no indication of
whether or not the resource was used. Where there was
incomplete indication of use of a resource (e.g. either
number or duration of contacts was given, but not both),
missing details were imputed using within-country, within-
group median values for resource users with relevant data.
In a few situations where there were no such valid cases
from which to impute we imputed using cross-country
within-group median values or, failing that, cross-country
cross-group medians.
Data on health and social care service use were relatively
complete (less than 2% missing for any particular service
at baseline and less than 3% at follow-up). The majority of
missing data occurred for two items – informal care and
medications. Up to 43 (11%) participants at baseline and
42 (11%) at follow-up reported receiving help with at least
one of the five categories of informal care but did not pro-
vide number of hours. For medications, between 9 and 43
(2% to 11%) participants at baseline and between 2 and 27
(1% to 7%) participants at follow-up had some data to
indicate medication use, but not enough to allow precise
cost estimation. Where medication name was available,
costs were imputed from available estimates for those
study participants taking the same medication. Where
medication name was unavailable, imputations were based
on overall medication cost data.
When calculating the costs of the adherence therapy
and health education interventions, we summed two
separate components, contact time and non-contact
time. Where there was an indication of the participant
attending at least one intervention session missing compo-
nents were imputed using within-country, within-group
median costs for those who with data.
Results
Participant characteristics
The sample were fairly typical of those seen in prevalence
studies of schizophrenia - a mean age of 42 years, 60%
male, 15% living with a partner, 40% living alone and 15%
employed - and were balanced between randomisation
groups (see Gray et al. [4] for further details).
Resource use
The data demonstrate the wide-ranging resource im-
pacts typically associated with schizophrenia. The most
heavily used services at both baseline and follow-up
were: psychiatric inpatient stays; psychiatric outpatient
visits; community mental health centre attendances;
psychiatrist contacts; primary care physician contacts;
and community psychiatric nurse/case manager contacts
(Table 2). At both assessments, virtually all participants
reported using one of the five classes of mental health
medications assessed for the study (anti-psychotics, anti-
depressants, benzodiazepines, mood stabilisers and anti-
cholinergics) and most had received anti-psychotics, the
mainstay of schizophrenia treatment. Use of benzodiaze-
pines appeared to be reduced in both groups at follow-
up, compared with baseline (41% and 35% in each group
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respectively at baseline, and down to 28% in both groups
at follow-up).
Approximately half of each group received informal
care from family and friends at baseline, mainly in the
form of help in and around the house and help with
activities outside of the home. Informal care receipt fell
to 36% at follow-up in both groups, although weekly
average hours of care received (among users) differed
between the groups (26 in the adherence therapy group
and 8 in the health education group). Rates of contact
with criminal justice system services were low.
Employment and time off work
Few people were employed. At baseline, four people in
the adherence therapy group and three in the health
education group were in voluntary employment at the time
of assessment. Twenty-one per cent (n = 42 and n = 43
in the adherence therapy and health education groups
respectively) were in paid, self-, sheltered or other em-
ployment. Nine per cent of participants in each group
had taken time off work due to illness in the past
3 months, totalling a mean (among those who took time
off work) of 34 days (SD = 36) in the adherence therapy
group and 27 days (SD = 32) in the health education
group.
At follow-up, three people in the adherence therapy
group and six in the health education group were in
voluntary work. Employment rates (for paid, self, shel-
tered or other work) were 16% (n = 28) in the adherence
therapy group and 20% (n = 40) in the health education
group. Four per cent (n = 7) of the adherence therapy
group took an average of 21 days (SD = 31) due to illness
in the past three months, while 7% (n = 14) in the health
education group took an average of 18 days (SD = 24)
days off.
Interventions
Participants in each group attended an average of 7 ad-
herence therapy sessions and 6 health education sessions
respectively (Table 3). There were more treatment com-
pleters in the adherence therapy group; 17 (9%) attended
four or less sessions (in fact, 5 attended none) and thus
did not meet treatment completion criteria. The health
education group had 37 (20%) non-completers, of whom 9
(4.9%) attended none. Adherence therapy sessions were
on average 6 minutes longer (95% confidence interval: 4
to 8); there were differences in non-contact time.
Costs
Average costs of adherence therapy and health education
interventions were 192 PPP-adjusted Euros and 138
PPP-adjusted Euros respectively (mean difference 54;
95% confidence interval 37, 70). While adherence therapy
cost more than health education, both appear relatively
inexpensive (although travel time by therapists and
patients are not included).
The majority of total societal costs were formed of
health and social care costs, with hospital inpatient costs
being the largest contributor. While the adherence ther-
apy group generally had lower costs than the health
education group at baseline, confidence intervals did
not suggest true differences (Table 4). There were no
between-group differences in either total health and
social care costs or societal costs at follow-up. Total
costs fell from baseline in both groups; inpatient costs
at follow-up were only 54–55% of those estimated at
baseline.
Outcomes
The groups were balanced on all outcome measures at
baseline (Table 5). Both groups showed improvements in
all outcome measures over time (untested) but there
were no differences between the groups at follow-up.
Cost-effectiveness and cost-utility
It was not necessary to calculate ICERs because none of
the six cost-outcome combinations examined involved
both greater costs and better outcomes for the adher-
ence therapy group. In fact, adherence therapy may be
‘dominated’ by health education or involve lower costs
alongside worse outcomes – an unlikely basis for choos-
ing a treatment. This conclusion is supported by the
spread of cost-outcome differences across all four quad-
rants of the cost-effectiveness plane (Figure 1) and the
slight tendency for estimates to extend further across
the south-west quadrant (which represents lower costs
and worse outcomes).
CEACs broadly confirmed the neutrality of the cost
and outcome findings, with probabilities of adherence
Table 2 Inputs related to adherence therapy and health education
Adherence therapy (n = 204) Health education (n = 205)
Valid n Mean Valid n Mean
Number of sessions 186 7 183 6
Session duration (minutes) 173 37 173 31
Total non-contact time across all sessions for attenders (minutes) 143 91 154 81
Total non-contact time across all sessions for non-attenders (minutes) 2 10 5 5
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Table 3 Resource use at baseline and 1 year follow-up (past 1 year for accommodation & inpatient services, past
3 months for all other services)
Adherence therapy (n = 204) Health education (n = 205)
Baseline 1 year follow-up Baseline 1 year follow-up
Valid
n
Users (n, %) Mean* Valid
n
Users
(n, %)
Mean1 Valid
n
Users (n, %) Mean1 Valid
n
Users
(n, %)
Mean1
Specialised accommodation 204 35 (17) 318 177 33 (19) 320 205 35 (17) 328 196 39 (20) 292
Secondary care
Psychiatric inpatient days 204 86 (42) 102 176 47 (27) 113 205 83 (41) 100 196 50 (26) 100
Non-psychiatric inpatient days 204 14 (7) 16 176 6 (3) 14 205 20 (10) 40 196 12 (6) 17
Psychiatric outpatient visits 204 47 (23) 2 177 26 (15) 2 205 53 (26) 3 196 39 (20) 1
Emergency department &
other outpatient visits
204 20 (10) 2 177 9 (5) 2 205 14 (7) 1 196 7 (4) 1
Day hospital visits 204 15 (7) 20 177 2 (1) 19 205 9 (4) 4 196 6 (3) 11
Community-based services
Community mental health
centre visits
204 54 (27) 18 177 60 (34) 19 205 49 (24) 18 196 57 (30) 17
Day care centre visits 204 23 (11) 20 177 14 (8) 16 205 18 (9) 32 196 19 (10) 21
Group therapy visits 204 3 (2) 21 177 3 (2) 21 205 4 (2) 7 196 1 (1) 12
Sheltered workshop visits 204 9 (4) 24 177 2 (1) 22 205 6 (3) 38 196 3 (2) 36
Specialist education visits 204 1 (< 1) 24 177 1 (1) 36 205 1 (< 1) 4 196 1 (1) 6
Primary and community care professionals
Psychiatrist contacts 204 140 (69) 4 177 118 (37) 4 205 145 (71) 4 195 143 (73) 3
Psychologist contacts 204 3 (2) 7 177 6 (3) 15 205 8 (4) 6 196 6 (3) 14
Primary care physician
contacts
204 86 (42) 2 177 80 (45) 2 205 90 (44) 3 195 84 (40) 2
District nurse contacts 204 3 (2) 27 177 3 (2) 32 205 2 (1) 7 196 4 (2) 26
Community psychiatric nurse/
case manager contacts
204 71 (35) 5 177 67 (38) 8 205 77 (38) 6 195 71 (36) 11
Social worker contacts 204 30 (15) 6 177 19 (11) 4 205 20 (10) 5 195 20 (10) 4
Occupational therapist
contacts
204 3 (2) 36 177 5 (3) 16 205 5 (2) 43 195 1 (1) 1
Home help/care worker
contacts
204 9 (4) 24 177 5 (3) 26 205 8 (4) 19 195 10 (5) 18
Medications
Antipsychotics 197 177 (90) 175 162 (93) 204 185 (91) 196 184 (94)
Antidepressants 195 60 (31) 173 52 (30) 204 45 (22) 196 47 (24)
Benzodiazepines 194 79 (41) 174 49 (28) 204 71 (35) 196 55 (28)
Mood stabilisers 194 20 (10) 173 17 (10) 204 23 (11) 196 22 (11)
Anticholinergics 195 26 (13) 173 29 (17) 204 33 (16) 196 32 (16)
Informal care hours per week 204 103 (50) 11 177 63 (36) 14 205 98 (48) 12 195 69 (35) 8
Criminal justice system
Police contacts 204 13 (6) 2 177 6 (3) 1 205 13 (6) 1 196 9 (5) 1
Nights spent in police cell or
prison
204 3 (1) 22 177 1 (1) 1 205 3 (1) 2 196 2 (1) 6
Psychiatric assessment whilst in
custody
204 2 (1) 1 177 0 - - 205 1
(< 1)
1 196 1 (1) 1
Criminal court appearances 204 1 (< 1) 1 177 0 - - 205 1 (< 1) 1 196 2 (1) 2
Civil court appearances 204 3 (1) 1 177 1 (1) 1 205 1 (< 1) 1 196 0 - -
1. Mean for those who used services.
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Table 4 Mean one-year costs at baseline and 1 year follow-up (PPP-adjusted Euros, 2011 prices)
Adherence therapy
(n = 204)
Health education
(n = 205)
Adherence therapy – Health education1
Valid
n
Mean (SD) Valid
n
Mean (SD) Unadjusted
comparisons
Baseline-adjusted
comparisons
Mean
difference
95%
confidence
interval
Mean
difference
95%
confidence
interval
Baseline
Accommodation 204 5637 (13837) 205 6676 (16508) −1039 −4323, 1640 na na
Inpatient services 204 13649 (30841) 205 12659 (27797) 990 −4440, 6253 na na
Outpatient services 204 686 (2938) 205 314 (794) 372 30, 884 na na
Community-based services 204 2973 (18688) 205 4532 (25686) −1559 −6200, 2912 na na
Community-based professionals 204 998 (1370) 205 1088 (2797) −90 −555, 289 na na
Medication 197 4400 (6387) 204 4103 (6405) 297 −1031, 1527 na na
Subtotal from health/social care
perspective
197 27427 (36015) 204 29484 (41535) −2057 −9916, 5882 na na
Informal care 204 5300 (12230) 205 5461 (14533) −161 −2756, 2667 na na
Time off work 202 1656 (7846) 204 1339 (6514) 316 −1190, 1631 na na
Criminal justice system 204 442 (4524) 205 368 (4440) 74 −862, 1012 na na
Sub-total for non-health/social care
costs
202 7451 (14805) 204 7197 (16157) 253 −3093, 3273 na na
Total from societal perspective 195 35190 (39442) 203 36828 (44573) −1638 −9801, 6719 na na
1 year follow-up
Adherence therapy or health education
intervention
204 192 (93) 205 138 (77) 54 37, 70
Accommodation 177 6112 (14523) 196 6504 (15953) −392 −3569, 2659 194 −1805, 2259
Inpatient services 176 7411 (20737) 196 6976 (22574) 435 −4025, 4732 418 −3719, 4318
Outpatient services 177 235 (832) 196 226 (613) 10 −137, 166 5 −144, 160
Community-based services 177 1350 (5108) 196 3865 (29011) −2515 −7420, 589 −237 −2168, 1298
Community-based professionals 177 1545 (6969) 195 1473 (6737) 72 −1267, 1405 76 −1324, 1411
Medication 175 3202 (3942) 196 3549 (4737) −347 −1285, 585 −483 −1268, 322
Subtotal from health/social care
perspective, including intervention cost
174 20115 (28339) 195 22597 (40727) −2483 −10017, 4448 −757 −5820, 4386
Subtotal from health/social care
perspective, excluding intervention cost
174 19919 (28332) 195 22459 (40720) −2540 −10075, 4385 −816 −5877, 4331
Informal care 177 4639 (17298) 194 2813 (6377) 1826 −634, 4602 1859 −611, 4532
Time off work 176 423 (3541) 196 699 (4146) −277 −1043, 506 −320 −1063, 408
Criminal justice system 177 40 (372) 196 978 (9963) −938 −2597, 46 −937 −2605, 46
Sub-total for non-health/social care
costs
176 5118 (17679) 194 4508 (12220) 610 −2282, 3881 596 −2451, 4000
Total from societal perspective,
including intervention cost
173 25346 (32406) 193 26787 (41743) −1442 −9722, 6213 10 −6915, 6235
Total from societal perspective,
excluding intervention cost
173 25149 (32404) 193 26648 (41737) −1499 −9774, 6153 −49 −6979, 6171
1. Based on bootstrapped linear regression of group upon cost (1000 repetitions).
na = not applicable to baseline comparisons.
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therapy being the most cost-effective option ranging
between 0.3 and 0.6 from both cost perspectives and for
all outcomes for the willingness to pay thresholds we
examined (Figure 2). Adherence therapy had greater
chances of being cost-effective from the health and
social care perspective (solid lines in Figure 2) than the
societal perspective (dotted lines).
Discussion
Effectiveness evidence from the QUATRO study suggested
that adherence therapy was equivalent to health education
in improving quality of life for people with schizophrenia
[4]. This economic evaluation confirms this equivalence
by finding no differences in costs (from either of two per-
spectives), quality-adjusted life years or cost-effectiveness.
Table 5 Outcomes at baseline and 1 year follow-up
Adherence therapy
(n = 204)
Health education
(n = 205)
Adherence therapy – Health education1
Valid
n
Mean (SD) Valid
n
Mean (SD) Unadjusted comparisons Baseline-adjusted comparisons
Mean
difference
95% confidence
interval
Mean
difference
95% confidence
interval
SF-36 MCS
Baseline 191 38.39 (11.22) 195 40.11 (12.15) −1.72 −4.14, 0.54 na na
1 year follow-up 175 40.24 (11.97) 192 41.32 (11.49) −1.08 −3.43, 1.42 −0.33 −2.41, 1.79
SF-36 utilities and QALYs
Baseline utility 191 0.66 (0.12) 192 0.68 (0.13) −0.02 −0.04, 0.01 na na
1 year follow-up
utility
177 0.68 (0.14) 190 0.69 (0.13) −0.01 −0.04, 0.02 −0.005 −0.03, 0.02
1 year QALY gain 166 0.67 (0.11) 179 0.68 (0.12) −0.01 −0.04, 0.01 −0.002 −0.01, 0.01
EQ5D utilities and QALYs
Baseline utility 196 0.67 (0.30) 198 0.69 (0.28) −0.02 −0.08, 0.03 na na
1 year follow-up
utility
174 0.68 (0.31) 193 0.74 (0.26) −0.06 −0.12, -0.003 −0.04 −0.09, 0.01
1 year QALY gain 170 0.67 (0.26) 188 0.72 (0.23) −0.05 −0.10, 0.01 −0.02 −0.05, 0.01
1. Based on bootstrapped linear regression of group upon cost (1000 repetitions).
na = not applicable to baseline comparisons.
-
10
00
0
0005
-
0
50
00
00001
-.02 -.01 0 .01 .02
Mean difference in SF-36-based QALYs
M
ea
n 
di
ffe
re
nc
e 
in
 h
ea
lth
 &
 s
oc
ia
l c
ar
e 
co
st
s
Figure 1 Cost-effectiveness plane (overall) of mean differences in SF36-based QALYs and mean differences in health and social care
costs (PPP-adjusted Euros).
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As the study shows small outcome improvements and
cost reductions over time in both groups, it is unclear
whether either intervention had any impact at all and
the changes simply reflect the natural course of partici-
pants’ recovery because they were recruited during a
clinically unstable period. While controlling for the time
and attention inputs was necessary, it causes difficulties
for interpreting the findings. It is possible that results
may have differed with a comparison of treatment as
usual [3]. Although many evaluations of adherence in-
terventions naturally assess impact on adherence to
medication, the QUATRO study focused on the more
over-arching outcome of quality of life (in the expect-
ation that this could be improved via lower symptoms
and better functioning) and found no such differences
over one year. We do not know whether such effects are
more likely to occur in the longer term or whether ad-
herence may not be a mediating factor in improving
quality of life, as also suggested in a more recent study
of an adherence therapy intervention for people with
psychotic disorders [23].
While there is a wealth of evidence suggesting that im-
provements in medication adherence are associated with
reductions in readmissions (e.g. see Staring et al. [23] for
a recent example), there is comparatively less by way of
‘formal’ economic evaluation of non-pharmacological
interventions (see Andrews et al. [24] for a recent
review). A randomised controlled trial of 74 people with
psychosis about to move from inpatient residence found
that those receiving compliance therapy were five times
more likely than those receiving non-specific counselling
to take their medication without prompting, and over an
18-month follow-up period had better global function-
ing, insight, adherence and attitudes to their medication
[25]. The associated economic evaluation (which took a
broad perspective incorporating health and social care
services, education, social security and housing supports,
and criminal justice contacts) found the two interven-
tions had similar costs during each of the three 6-month
follow-up phases and over the full 18 months [26]. Com-
bined with improved outcomes, this suggested cost-
effectiveness. Significant correlations were found between
greater adherence and higher costs over the first six
months. Therefore, improving adherence initially in-
creased costs, although there was an offsetting reduc-
tion over time.
Our study has several strengths. It took a broad cost
perspective, which is a necessity to encompass the many
and broad-ranging impacts that schizophrenia incurs
[27]. The study also had an exceptionally good follow-up
rate with minimal missing data among those that were
followed up, although it is unclear what the effect on
findings may have been if those lost to follow-up had
been included given that they had higher costs at baseline
compared with those followed up. Finally, this multi-
country economic evaluation was undertaken by applying
mostly country-specific unit costs to country-specific
resource use data, and conducting pooled analyses based
on costs converted to a common currency using purchas-
ing power parities. This combination of approaches had
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the advantages of preserving the within-country link be-
tween resource use, costs and outcomes and maintaining
a large sample size (generally, but especially so in the con-
text of schizophrenia studies).
However, the multi-country approach also carries
methodological challenges (such as wide-scale unit cost
collation) and limitations for interpretation and generalis-
ability; for example, there may be variations in adherence
to anti-psychotic medication due to broad contextual fac-
tors such as culture or ethnicity [28] which in turn impact
on costs [29]. We did not intend to examine costs and
cost-effectiveness for each site separately because of insuf-
ficient sample size for such sub-group analyses (moving
away from statistical significance towards the CEAC
approach doesn’t necessarily make small sample studies
acceptable [5]). Despite similarities in quality of life out-
comes between sites, there were variations in resource
use, unit costs and resource costs and this may affect the
application of the findings to the individual study coun-
tries and for policy-making. Such observations could also
arise in multi-centre studies carried out within a single
country, but are more noticeable in multi-national studies
perhaps simply because we are more likely to look for
them in this situation. For example, in examining the
relative contribution of different resources to total cost,
Leipzig shows the greatest difference as compared to
the other sites and the pooled results. Its specialised ac-
commodation costs were relatively low compared to the
other sites, which is probably due to few such facilities
existing there. It also had higher medication costs, both
in absolute terms and in terms of the proportion they
contribute to total costs, which likely due to greater
medication use, rather than differing unit costs, given
that all medication costs were based on UK prices. Al-
though there were no statistically significant differences
in total health and social care costs between the two
groups at one year follow-up at any of the individual
sites, there were marked differences in the size of the
observed mean (baseline-adjusted) difference: -8868
PPP-adjusted Euros in Leipzig (i.e. a cost saving in the
adherence therapy group) to 5421 PPP-adjusted Euros
in London (i.e. a cost saving in the health education
group). The impact of such variations is apparent in
site-specific CEACs (Figure 3), with probabilities of the
cost-effectiveness of adherence therapy being highest in
Leipzig and lowest in London, for the threshold range
examined. While we are cautious about focusing on
these site-specific findings due to sample size limita-
tions, they clearly suggest that the potential value of
adherence therapy varies across sites and that pooled
analyses in trials may not portray such variations. This
is an important finding because multi-country trials are
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increasingly used to increase sample size, speed up
recruitment and/or increase generalisability. We further
explored the impact on site-specific CEACs when costs
are analysed in their local currency, rather than being
standardised to a common currency, whilst being kept
at their original price year of 2003, rather than being
inflated to recent price levels using an inflation rate
(GDP-based) that may or may not accurately reflect
changes in health care costs over time. This had virtually
no impact on the probabilities of cost-effectiveness for
each site, with values for all threshold levels varying by
no more than 0.007 points away from those obtained
from inflated PPP-adjusted Euros.
Conclusions
This study confirms the substantial costs that are required
to care for people with schizophrenia and thus the need
for cost-effective support for this group of people. This
evaluation suggests that adherence therapy doesn’t meet
that need when the focus in on quality of life. The clarity
of this conclusion is affected by the unknown impact of
using an active, rather than treatment as usual, control,
uncertainty about the ability of such interventions to
impact on quality of life in the short-term and variations
in the cost-effectiveness of adherence therapy across the
sites.
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